Talipes Equinovarus Treatment in Infants Treated by the Ponseti Method Compared With Posterior-Only Release: A Mid-Childhood Comparison of Results

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ferrando, A
  • Page, A
  • Atienza, C
  • Minguez, MF
  • Prat, J

Grupos

Abstract

The aim of this study is to evaluate children in middle childhood with clubfoot treated with Ponseti method vs posterior-only release and to compare their results to a control group with 4 modules (physical examination, gait study, radiographic measurements, and questionnaires). From 01/01/2004 until 01/01/2009, 31 children (45 feet) were treated with the posterior-only release protocol and 22 patients (34 feet) were treated with the Ponseti method. In 2016, patients were evaluated and compared with 25 children without neuromuscular disorders. Parents completed 3 outcome questionnaires. Radiographs evaluated residual deformity and osteoarthritis. A physical examination and a 3-dimensional gait analysis were performed to evaluate range of motion, kinematic, and kinetic data. Recurrence rate was similar between treatment groups; however, type of surgery to treat residual deformity was more aggressive in the posterior-only release (91% required major surgery), p= .024. Radiographic examination showed similar residual deformity with greater hindfoot varus in posterior-only release (68%), p = .02. Reduced cadence, increased stance dorsiflexion, calcaneus gait and forced eversion prior to swing were the main characteristics of gait in posterior-only release. Four (11%) feet treated with posterior-only release vs 11 (33%) feet treated with Ponseti method had a normal gait, p = .016. Our study showed that biomechanical function and long-term outcomes of children in middle childhood treated with the Ponseti method more closely compare with healthy individuals than those treated using posterior-only surgical technique. (C) 2020 by the American College of Foot and Ankle Surgeons. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1067-2516, 1542-2224

JOURNAL OF FOOT & ANKLE SURGERY  W. B. Saunders Co., Ltd.

Tipo:
Article
Páginas:
919-926
PubMed:
32482579
Factor de Impacto:
0,653 SCImago
Cuartil:
Q2 SCImago

Citas Recibidas en Web of Science: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • clubfoot; foot; gait analysis; Ponseti; posterior-only release; talus

Proyectos y Estudios Clínicos

BIOMARCADORES DINÁMICOS BASADOS EN FIRMAS TISULARES MULTIPARAMÉTRICAS PARA EL SEGUIMIENTO Y EVALUACIÓN DE LA RESPUESTA A TRATAMIENTO DE PACIENTES CON GLIOBLASTOMA Y CANCER DE PRÓSTATA.

Investigador Principal: JUAN MIGUEL GARCÍA GÓMEZ

2016_0704_CPC_GARCIA_GOMEZ . 2016

Multicentre prospective study of diagnostic accuracy for quantification by Magnetic Resonance multiparametric imaging of liver fibrosis, inflammation, steatosis, iron and vascular resistance.

Investigador Principal: LUIS MARTÍ BONMATÍ

PI19/00380 . INSTITUTO DE SALUD CARLOS III . 2020

ESTUDIO EN FASE III SOBRE ERDAFITINIB EN COMPARACIÓN CON VINFLUNINA, DOCETAXEL O PEMBROLIZUMAB EN SUJETOS CON CARCINOMA UROTELIAL AVANZADO Y ANOMALÍAS GENÉTICAS SELECCIONADAS EN FGFR.

Investigador Principal: REGINA GIRONÉS SARRIÓ

42756493-BLC3001 . 2018

ESTUDIO DE FASE 3, DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO, MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DEL ÁCIDO OBETICÓLICO EN PACIENTES CON CIRROSIS COMPENSADA DEBIDA A ESTEATOHEPATITIS NO ALCOHÓLICA.

Investigador Principal: MARINA BERENGUER HAYM

747-304 . 2018

ESTUDIO EN FASE II, MULTICÉNTRICO, ABIERTO Y DE UN SOLO GRUPO DE ENCORAFENIB, BINIMETINIB MÁS CETUXIMAB EN SUJETOS CON CÁNCER COLORRECTAL METASTÁSICO CON MUTACIÓN BRAFV600E SIN TRATAMIENTO PREVIO.

Investigador Principal: JORGE APARICIO URTASUN

W00090GE201 . 2018

A PHASE 3, RANDOMIZED, COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH BACILLUS CALMETTE- GUERIN (BCG) IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR NMIBC) THAT IS PERSISTENT OR RECURRENT FOLLOWING BCG INDUCTION (KEYNOTE-676)

Investigador Principal: REGINA GIRONÉS SARRIÓ

MK-3475-676 . 2018

ESTUDIO FASE III ALEATORIZADO DE NIRAPARIB EN COMBINACIÓN CON ACETATO DE ABIRATERONA Y PREDNISONA PARA EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA METASTÁSICO.

Investigador Principal: REGINA GIRONÉS SARRIÓ

64091742PCR3001 . 2019

A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER, THE COMBAT STUDY.

Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE

BL-8040.PAC.201 . 2019

ESTUDIO PROSPECTIVO OBSERVACIONAL DE LA EXPRESIÓN DE ABCB1/P-GLICOPROTEÍNA COMO FACTOR PARA LA ESTRATIFICACIÓN BIOLÓGICA DEL OSTEOSARCOMA NO METASTÁTICO DE LAS EXTREMIDADES.

Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE

ISG-GEIS-OS-2 . 2014

Cita

Compartir